Drug intelligence / Profile preview

PrevEp003

Development stage: Discontinued
Lead developer: Prevep
Modality: Small Molecules

Overview

**PrevEp003** is a paused discovery-stage triple small-molecule antiepileptic combination developed by Prevep for prevention of post-traumatic epilepsy. It combines levetiracetam, topiramate, and gabapentin to address multiple epileptogenic processes through synaptic vesicle glycoprotein 2A modulation, inhibition of AMPA and kainate glutamate receptor signaling, modulation of voltage-dependent calcium-channel pathways, and enhancement of GABAergic inhibitory signaling.

Other names: levetiracetam + topiramate + gabapentin

Targets

AMPAR (AMPA receptor)GABRR (GABA-A receptor subunit rho)Kainate-type ionotropic glutamate receptorα2δ (Voltage-gated calcium channel alpha-2-delta subunit)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on PrevEp003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrevEp003.

Explore the full profile